<DOC>
	<DOCNO>NCT01580735</DOCNO>
	<brief_summary>The primary objective study examine combination regimen ARQ 197 erlotinib active subject locally advance metastatic NSCLC activate mutation EGFR progress EGFR-TKI monotherapy .</brief_summary>
	<brief_title>ARQ 197 Plus Erlotinib Patient With Locally Advanced Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Key Histologically cytologically confirm surgically unresectable locally advanced metastatic ( stage IIIB/IV ) NSCLC EGFR activate mutation . Measurable disease document disease progression follow first immediate EGFRTKI monotherapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate organ function Key Prior therapy cMet inhibitor . Any systemic antitumor treatment NSCLC within 7 day prior randomization . Major surgical procedure within 4 week prior randomization Known symptomatic brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>c-MET</keyword>
	<keyword>EGFR mutation-positive</keyword>
	<keyword>gefitinib</keyword>
	<keyword>erlotinib</keyword>
	<keyword>EGFR-TKI resistance</keyword>
</DOC>